Skip to content

Released Aug 16, 2021, after the close

10-Q filed Aug 16, 2021, 47 days after period end · 0001193125-21-247879

Q2 2021 · 10-Q
Revenue—
Net Income-$61.36MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$141.93N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$3,441,000N/M
Operating Cash Flowderived-$4,264,000—

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020
Net Income-$61.36M-$2.04M
EPS Diluted-$141.93-$4.86

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR